Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
Arrowhead Pharmaceuticals (ARWR) is preparing for a Q2 2026 launch of Redemplo in severe hypertriglyceridemia (sHTG), despite Ionis Pharmaceuticals' (IONS) disappointing sales of Tryngolza. Kyverna Therapeutics (KYV) deprioritized KYV-102, focusing on miv-cel for stiff-person syndrome. Prime Medicine (PRME) advances PM577a in Wilson’s disease and PM647 in AATD. Cullinan Therapeutics (CGEN) awaits data from CLN-978 and CLN-049 trials.


